USF Health
Welcome,         Profile    Billing    Logout  
 37 Trials 
154 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Leuchter, Andrew F
NCT04279522: The MOOD Study - External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for the Treatment of Major Depressive Disorder (MDD)

Completed
N/A
126
US, RoW
Relivion®DP- Active, Relivion®DP- Sham
Neurolief Ltd.
MDD
06/24
06/24
ABT-CIP-10494, NCT06423430: Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

Recruiting
N/A
100
US
Sham-stimulation, Active-stimulation
Abbott Medical Devices
Treatment Resistant Depression
04/27
04/29
Reinisch, Walter
ASPIRE, NCT04118088 / 2017-002491-10: A Study of Darvadstrocel in Adults With Crohn's Disease and Complex Perianal Fistula

Terminated
4
53
Europe, RoW
Darvadstrocel, Alofisel, Cx601
Takeda, Takeda Development Center Americas, Inc.
Crohn's Disease, Complex Perianal Fistula
02/25
02/25
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

Active, not recruiting
3
160
Europe, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic
08/24
09/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Active, not recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
VICTRIVA, NCT06227910: A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

Recruiting
3
396
Europe, Canada, US, RoW
Vedolizumab, Entyvio, MLN0002, KYNTELES, Upadacitinib, Rinvoq, Placebo
Takeda
Crohn's Disease
06/27
08/28
COMMIT-CD, NCT06937099: Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Not yet recruiting
3
290
Europe, Canada, US, RoW
Mirikizumab, LY3074828, Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Crohn's Disease, Obesity or Overweight
05/28
05/28
COMMIT-UC, NCT06937086: Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Not yet recruiting
3
350
Europe, Canada, US, RoW
Mirikizumab, LY3074828, Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Ulcerative Colitis, Obesity or Overweight
04/28
04/28
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
Winner, Paul K
TRAILBLAZER-ALZ 6, NCT05738486: A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease

Active, not recruiting
3
1100
Europe, US
Donanemab, LY3002813, Placebo, Dexamethasone
Eli Lilly and Company
Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
05/24
05/25
APOLLOE4-LTE, NCT06304883: Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

Active, not recruiting
3
163
Europe, Canada, US
Experimental: ALZ-801
Alzheon Inc.
Early Alzheimer's Disease
12/26
01/27
RETHINK-1, NCT04994483: Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease

Completed
3
804
Canada, US, RoW
Simufilam, PTI-125, Placebo
Cassava Sciences, Inc., Premier Research Group plc
Alzheimer Disease
10/24
10/24
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Remternetug, LY3372993, Placebo
Eli Lilly and Company
Alzheimer's Disease
04/29
10/30
TRAILRUNNER-ALZ 1, NCT05463731: A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease

Active, not recruiting
3
1667
Japan, US
Remternetug (IV), LY3372993, Remternetug (SC), Placebo
Eli Lilly and Company
Alzheimer's Disease
04/24
03/26
ALITHIOS, NCT03650114 / 2017-004703-51: Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Calendar Jan 2028 - Dec 2028: Data from ALITHIOS trial for multiple sclerosis
Active, not recruiting
3
1882
Europe, Canada, Japan, US, RoW
Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
12/27
09/28
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1633
Europe, Japan, US, RoW
Lasmiditan, LY573144, Placebo
Eli Lilly and Company
Migraine
11/26
11/26
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1000
Europe, Japan, US, RoW
Lasmiditan, LY573144
Eli Lilly and Company
Migraine
01/28
01/28
LIFT-AD, NCT04488419: ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

Completed
2/3
554
US
ATH-1017, Placebo
Athira Pharma
Alzheimer Disease, Dementia of Alzheimer Type
07/24
07/24
NCT06538116: A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease

Recruiting
2
300
Japan, US
Mevidalen, LY3154207, Placebo
Eli Lilly and Company
Alzheimer Disease
12/25
01/26
SIGNAL-AD, NCT04381468: SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)

Completed
1/2
50
US
Pepinemab, Placebo
Vaccinex Inc., Alzheimer's Drug Discovery Foundation, Alzheimer's Association
Alzheimer Disease
06/24
06/24
Davis, Ronald
SKYWAY, NCT04938427 / 2021-002481-40: A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome

Completed
3
270
Europe, Canada, Japan, US, RoW
Placebo, Soticlestat, TAK-935
Takeda
Lennox Gastaut Syndrome (LGS)
01/24
01/24
SKYLINE, NCT04940624 / 2021-002480-22: A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome

Completed
3
144
Europe, Canada, Japan, US, RoW
Soticlestat, TAK-935, Placebo
Takeda
Dravet Syndrome (DS)
04/24
04/24
ARGUS, NCT04462770 / 2021-003425-30: A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

Recruiting
3
150
Europe, Canada, US, RoW
Clemizole HCl, EPX-100, Placebo
Epygenix, Harmony Biosciences Management, Inc.
Dravet Syndrome
04/26
05/29
D1AMOND, NCT05615220: Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults

Completed
3
216
Europe, Canada, US, RoW
Ecopipam Hydrochloride
Emalex Biosciences Inc.
Tourette Disorder
01/25
02/25
ENDYMION 2, NCT05163314 / 2021-002482-17: A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome

Active, not recruiting
3
400
Europe, Canada, Japan, US, RoW
Soticlestat, TAK-935
Takeda
Dravet Syndrome (DS), Lennox Gastaut Syndrome (LGS)
05/26
05/26
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1633
Europe, Japan, US, RoW
Lasmiditan, LY573144, Placebo
Eli Lilly and Company
Migraine
11/26
11/26
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1000
Europe, Japan, US, RoW
Lasmiditan, LY573144
Eli Lilly and Company
Migraine
01/28
01/28
NCT03734731: Cannabis Vs Opioids Pain Management Objective Testing Comparisons

Not yet recruiting
N/A
1000
NA
Monochromatic Infrared Photo Energy (MIRE), Transcutaneous Electrical Nerve Stimulation, Opioids, Cannabis, Marijuana
American Association of Sensory Electrodiagnostic Medicine
Chronic Pain, Circulatory Disorders
01/26
01/26
Reese, Randall
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

Recruiting
3
300
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Chronic Migraine
07/25
03/26
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

Recruiting
3
325
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Episodic Migraine
11/25
11/26
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1633
Europe, Japan, US, RoW
Lasmiditan, LY573144, Placebo
Eli Lilly and Company
Migraine
11/26
11/26
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1000
Europe, Japan, US, RoW
Lasmiditan, LY573144
Eli Lilly and Company
Migraine
01/28
01/28
NCT05412030: A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

Active, not recruiting
2
472
US
AFX3772, Prevnar 13, PCV13, Prevnar 20, PCV20
GlaxoSmithKline, Affinivax, Inc.
Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
07/26
07/26
McConnehey, Brock
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Remternetug, LY3372993, Placebo
Eli Lilly and Company
Alzheimer's Disease
04/29
10/30
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Active, not recruiting
3
1576
Japan, US, RoW
Orforglipron, LY3502970, Semaglutide
Eli Lilly and Company
Type 2 Diabetes
09/25
09/25
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

Recruiting
3
300
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Chronic Migraine
07/25
03/26
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

Recruiting
3
325
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Episodic Migraine
11/25
11/26
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting
3
2996
Japan, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer Disease
11/27
11/27
Kalidas, Kavita
CHALLENGE-MIG, NCT05127486: A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine

Checkmark Enrollment initiated in combination with Emgality for episodic migraine
Nov 2021 - Nov 2021: Enrollment initiated in combination with Emgality for episodic migraine
Completed
4
580
US
Galcanezumab, LY2951742, Rimegepant, Placebo
Eli Lilly and Company
Migraine, Episodic Migraine
05/23
05/23
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

Recruiting
3
300
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Chronic Migraine
07/25
03/26
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

Recruiting
3
325
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Episodic Migraine
11/25
11/26
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1633
Europe, Japan, US, RoW
Lasmiditan, LY573144, Placebo
Eli Lilly and Company
Migraine
11/26
11/26
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1000
Europe, Japan, US, RoW
Lasmiditan, LY573144
Eli Lilly and Company
Migraine
01/28
01/28
Taylor, Kelly
CHALLENGE-MIG, NCT05127486: A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine

Checkmark Enrollment initiated in combination with Emgality for episodic migraine
Nov 2021 - Nov 2021: Enrollment initiated in combination with Emgality for episodic migraine
Completed
4
580
US
Galcanezumab, LY2951742, Rimegepant, Placebo
Eli Lilly and Company
Migraine, Episodic Migraine
05/23
05/23
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

Recruiting
3
300
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Chronic Migraine
07/25
03/26
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

Recruiting
3
325
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Episodic Migraine
11/25
11/26
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1633
Europe, Japan, US, RoW
Lasmiditan, LY573144, Placebo
Eli Lilly and Company
Migraine
11/26
11/26
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1000
Europe, Japan, US, RoW
Lasmiditan, LY573144
Eli Lilly and Company
Migraine
01/28
01/28
GLY-200-03, NCT06259981: A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity

Active, not recruiting
2
75
US
GLY-200, Placebo
Glyscend, Inc.
Obesity
12/24
12/24
Moore, Joseph O
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

Recruiting
3
300
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Chronic Migraine
07/25
03/26
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

Recruiting
3
325
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Episodic Migraine
11/25
11/26
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1633
Europe, Japan, US, RoW
Lasmiditan, LY573144, Placebo
Eli Lilly and Company
Migraine
11/26
11/26
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1000
Europe, Japan, US, RoW
Lasmiditan, LY573144
Eli Lilly and Company
Migraine
01/28
01/28
NCT06143956: A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Recruiting
2
1040
US, RoW
LY3305677, LY3841136, Tirzepatide, Placebo, LY3549492
Eli Lilly and Company
Obesity, Overweight
06/26
09/26
NCT06230523: A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

Active, not recruiting
2
250
US, RoW
LY3841136, Placebo
Eli Lilly and Company
Obesity, Overweight and Obesity
06/25
09/25
NCT06603571: A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Recruiting
2
350
US, RoW
LY3841136, Tirzepatide, Placebo
Eli Lilly and Company
Obesity, Overweight
06/26
08/26
NCT06683508: A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

Active, not recruiting
2
275
US
LY3549492, Placebo
Eli Lilly and Company
Obesity, Overweight
04/26
09/26
Fernandez, Joel Garcia
PROACTIVE-HF, NCT04089059: IDE Trial Heart Failure NYHA Class III

Active, not recruiting
N/A
738
Europe, US
Cordella™ Pulmonary Artery Sensor System
Endotronix, Inc.
Heart Failure NYHA Class III
04/28
04/28
Phan, Han
RESPOND, NCT04488133 / 2020-003492-18: A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec

Active, not recruiting
4
46
Europe, US, RoW
Nusinersen, ISIS 396443, BIIB058, Spinraza
Biogen
Muscular Atrophy, Spinal
10/25
10/25
RECONNECT, NCT04977986 / 2021-002542-33: Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome

Active, not recruiting
3
215
Europe, US, RoW
ZYN002 - transdermal gel, cannabidiol formulated as a clear gel that can be applied to the skin (transdermal delivery), Placebo, Placebo Comparator, Matching Placebo
Zynerba Pharmaceuticals, Inc., Zynerba Pharmaceuticals, Inc.
Fragile X Syndrome
05/25
05/25
EBS-101-TD-391, NCT06021522: A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder

Recruiting
3
150
Europe, Canada, US, RoW
Ecopipam, Ecopipam Hydrochloride
Emalex Biosciences Inc.
Tourette Syndrome
12/26
03/27
MIS51ON, NCT03992430 / 2018-001762-42: A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD)

Active, not recruiting
3
160
Europe, US, RoW
Eteplirsen, AVI-4658, EXONDYS 51, EXONDYS
Sarepta Therapeutics, Inc., Sarepta Therapeutics, Inc.
Muscular Dystrophy, Duchenne
10/26
10/26
HOPE-3, NCT05126758: A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

Active, not recruiting
3
104
US
Deramiocel (CAP-1002), Cardiosphere-Derived Cells (CDCs), Placebo
Capricor Inc.
Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases, Neuromuscular Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn, Nervous System Diseases
12/25
12/27
D1AMOND, NCT05615220: Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults

Completed
3
216
Europe, Canada, US, RoW
Ecopipam Hydrochloride
Emalex Biosciences Inc.
Tourette Disorder
01/25
02/25
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

Recruiting
3
300
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Chronic Migraine
07/25
03/26
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

Recruiting
3
325
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Episodic Migraine
11/25
11/26
ASCEND, NCT05067790 / 2021-001294-23: A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam

Active, not recruiting
3
45
Europe, Japan, US, RoW
Nusinersen, BIIB058, Spinraza
Biogen
Spinal Muscular Atrophy
06/27
06/27
Fortify, NCT05775848: Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)

Active, not recruiting
3
81
Europe, US, RoW
BBP-418 (ribitol), Placebo
ML Bio Solutions, Inc.
Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
07/27
07/27
NCT04336826 / 2020-000980-21: A Study to Evaluate the Safety and Pharmacokinetics of Ataluren in Participants From ≥6 Months to <2 Years of Age With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

Completed
2
6
US
Ataluren, PTC124
PTC Therapeutics
Nonsene Mutation Duchenne Muscular Dystrophy
08/23
08/23
MOMENTUM, NCT04004065 / 2019-000601-77: Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment

Checkmark From MOMENTUM trial for DMD
May 2021 - May 2021: From MOMENTUM trial for DMD
Checkmark Interim data from the MOMENTUM study
Dec 2020 - Dec 2020: Interim data from the MOMENTUM study
Checkmark Data from MOMENTUM trial for Duchenne muscular dystrophy
More
Terminated
2
62
Europe, Canada, US
Vesleteplirsen, SRP-5051
Sarepta Therapeutics, Inc.
Duchenne Muscular Dystrophy
10/23
02/25
PWS-001, NCT05879614: An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome

Withdrawn
2
20
US
NNZ-2591, Cyclo-L-Glycyl-L-2-Allylproline
Neuren Pharmaceuticals Limited
Prader-Willi Syndrome
06/25
06/25
NCT06332807: AAV Gene Therapy Clinical Study in Adult Classic PKU (PHEdom)

Recruiting
1/2
12
US
NGGT002
NGGT INC.
Phenylketonurias
12/30
12/30
DELIVER, NCT05524883 / 2021-005478-24: Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

Active, not recruiting
1/2
86
Europe, Canada, US, RoW
DYNE-251, Placebo
Dyne Therapeutics, Dyne Therapeutics, Inc
Duchenne Muscular Dystrophy (DMD)
11/29
11/29
NCT05683379: AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Boys With DMD

Recruiting
N/A
200
US
AAV8 DetectCDx
REGENXBIO Inc.
Duchenne Muscular Dystrophy
09/26
09/26
Moretz, Katherine McNaughton
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

Recruiting
3
325
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Episodic Migraine
11/25
11/26
NCT05067634 / 2020-005344-27: Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

Recruiting
3
140
Europe, US, RoW
Xcopri
SK Life Science, Inc.
Partial Epilepsy
05/26
07/26
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1633
Europe, Japan, US, RoW
Lasmiditan, LY573144, Placebo
Eli Lilly and Company
Migraine
11/26
11/26
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1000
Europe, Japan, US, RoW
Lasmiditan, LY573144
Eli Lilly and Company
Migraine
01/28
01/28
Wilson, David R
NCT04154488: A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders

Completed
1/2
32
US
Mavorixafor, X4P-001
X4 Pharmaceuticals
Neutropenia
08/24
08/24
NCT01736592: Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration

Calendar Jan 2034 - Dec 2034: Data in Stargardt’s macular degeneration
Active, not recruiting
1/2
27
Europe, US
Long term follow up in all patients who received SAR422459 in previous study TDU13583
Sanofi
Stargardt's Disease
08/33
08/33
IMPRoVED-AF, NCT06935591: Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study

Not yet recruiting
N/A
384
Europe, US
Pulmonary Vein Isolation, vMap® + Pulmonary Vein Isolation
Vektor Medical, Veranex Switzerland SA
Atrial Fibrillation (AF)
10/27
12/27
NCT04165564: DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers

Active, not recruiting
N/A
85
US
Institutional standard of care, Biosamples of airway and blood
Boston University, Johnson & Johnson, American College of Radiology Imaging Network
Pulmonary Disease
12/26
12/26
NCT05412927: AngelMed Guardian® System PMA Post Approval Study

Recruiting
N/A
500
US
PMA P150009 AngelMed Guardian® System
Angel Medical Systems
Acute Coronary Syndrome
12/26
12/26
Boratto, Sandra
ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting
3
612
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Active, not recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
Soucie, Gary
QWINT-4, NCT05462756 / 2021-005878-25: A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

Completed
3
730
Europe, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Lispro (U100), Humalog, Insulin Glargine (U100), Basaglar
Eli Lilly and Company, Eli Lilly and Company
Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
02/24
02/24
ATTAIN-OSA, NCT06649045: A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Recruiting
3
600
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
OSA, Overweight or Obesity
11/26
01/27
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

Recruiting
3
300
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Chronic Migraine
07/25
03/26
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting
3
3000
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Overweight or Obesity
07/25
07/27
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

Recruiting
3
325
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Episodic Migraine
11/25
11/26
TRIUMPH-3, NCT05882045: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Active, not recruiting
3
1800
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Cardiovascular Diseases
01/26
02/26
TRIUMPH-4, NCT05931367: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee

Active, not recruiting
3
405
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Overweight, Osteo Arthritis Knee
12/25
12/25
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
Diaz, Doris Perez
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1633
Europe, Japan, US, RoW
Lasmiditan, LY573144, Placebo
Eli Lilly and Company
Migraine
11/26
11/26
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1000
Europe, Japan, US, RoW
Lasmiditan, LY573144
Eli Lilly and Company
Migraine
01/28
01/28
Haller, Andrea
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1633
Europe, Japan, US, RoW
Lasmiditan, LY573144, Placebo
Eli Lilly and Company
Migraine
11/26
11/26
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1000
Europe, Japan, US, RoW
Lasmiditan, LY573144
Eli Lilly and Company
Migraine
01/28
01/28
Goldstein, Gary I
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1633
Europe, Japan, US, RoW
Lasmiditan, LY573144, Placebo
Eli Lilly and Company
Migraine
11/26
11/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Leuchter, Andrew F
NCT04279522: The MOOD Study - External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) for the Treatment of Major Depressive Disorder (MDD)

Completed
N/A
126
US, RoW
Relivion®DP- Active, Relivion®DP- Sham
Neurolief Ltd.
MDD
06/24
06/24
ABT-CIP-10494, NCT06423430: Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

Recruiting
N/A
100
US
Sham-stimulation, Active-stimulation
Abbott Medical Devices
Treatment Resistant Depression
04/27
04/29
Reinisch, Walter
ASPIRE, NCT04118088 / 2017-002491-10: A Study of Darvadstrocel in Adults With Crohn's Disease and Complex Perianal Fistula

Terminated
4
53
Europe, RoW
Darvadstrocel, Alofisel, Cx601
Takeda, Takeda Development Center Americas, Inc.
Crohn's Disease, Complex Perianal Fistula
02/25
02/25
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

Active, not recruiting
3
160
Europe, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic
08/24
09/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Active, not recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
VICTRIVA, NCT06227910: A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

Recruiting
3
396
Europe, Canada, US, RoW
Vedolizumab, Entyvio, MLN0002, KYNTELES, Upadacitinib, Rinvoq, Placebo
Takeda
Crohn's Disease
06/27
08/28
COMMIT-CD, NCT06937099: Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Not yet recruiting
3
290
Europe, Canada, US, RoW
Mirikizumab, LY3074828, Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Crohn's Disease, Obesity or Overweight
05/28
05/28
COMMIT-UC, NCT06937086: Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Not yet recruiting
3
350
Europe, Canada, US, RoW
Mirikizumab, LY3074828, Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Ulcerative Colitis, Obesity or Overweight
04/28
04/28
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
Winner, Paul K
TRAILBLAZER-ALZ 6, NCT05738486: A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease

Active, not recruiting
3
1100
Europe, US
Donanemab, LY3002813, Placebo, Dexamethasone
Eli Lilly and Company
Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
05/24
05/25
APOLLOE4-LTE, NCT06304883: Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

Active, not recruiting
3
163
Europe, Canada, US
Experimental: ALZ-801
Alzheon Inc.
Early Alzheimer's Disease
12/26
01/27
RETHINK-1, NCT04994483: Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease

Completed
3
804
Canada, US, RoW
Simufilam, PTI-125, Placebo
Cassava Sciences, Inc., Premier Research Group plc
Alzheimer Disease
10/24
10/24
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Remternetug, LY3372993, Placebo
Eli Lilly and Company
Alzheimer's Disease
04/29
10/30
TRAILRUNNER-ALZ 1, NCT05463731: A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease

Active, not recruiting
3
1667
Japan, US
Remternetug (IV), LY3372993, Remternetug (SC), Placebo
Eli Lilly and Company
Alzheimer's Disease
04/24
03/26
ALITHIOS, NCT03650114 / 2017-004703-51: Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Calendar Jan 2028 - Dec 2028: Data from ALITHIOS trial for multiple sclerosis
Active, not recruiting
3
1882
Europe, Canada, Japan, US, RoW
Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
12/27
09/28
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1633
Europe, Japan, US, RoW
Lasmiditan, LY573144, Placebo
Eli Lilly and Company
Migraine
11/26
11/26
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1000
Europe, Japan, US, RoW
Lasmiditan, LY573144
Eli Lilly and Company
Migraine
01/28
01/28
LIFT-AD, NCT04488419: ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

Completed
2/3
554
US
ATH-1017, Placebo
Athira Pharma
Alzheimer Disease, Dementia of Alzheimer Type
07/24
07/24
NCT06538116: A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease

Recruiting
2
300
Japan, US
Mevidalen, LY3154207, Placebo
Eli Lilly and Company
Alzheimer Disease
12/25
01/26
SIGNAL-AD, NCT04381468: SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)

Completed
1/2
50
US
Pepinemab, Placebo
Vaccinex Inc., Alzheimer's Drug Discovery Foundation, Alzheimer's Association
Alzheimer Disease
06/24
06/24
Davis, Ronald
SKYWAY, NCT04938427 / 2021-002481-40: A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome

Completed
3
270
Europe, Canada, Japan, US, RoW
Placebo, Soticlestat, TAK-935
Takeda
Lennox Gastaut Syndrome (LGS)
01/24
01/24
SKYLINE, NCT04940624 / 2021-002480-22: A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome

Completed
3
144
Europe, Canada, Japan, US, RoW
Soticlestat, TAK-935, Placebo
Takeda
Dravet Syndrome (DS)
04/24
04/24
ARGUS, NCT04462770 / 2021-003425-30: A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome

Recruiting
3
150
Europe, Canada, US, RoW
Clemizole HCl, EPX-100, Placebo
Epygenix, Harmony Biosciences Management, Inc.
Dravet Syndrome
04/26
05/29
D1AMOND, NCT05615220: Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults

Completed
3
216
Europe, Canada, US, RoW
Ecopipam Hydrochloride
Emalex Biosciences Inc.
Tourette Disorder
01/25
02/25
ENDYMION 2, NCT05163314 / 2021-002482-17: A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome

Active, not recruiting
3
400
Europe, Canada, Japan, US, RoW
Soticlestat, TAK-935
Takeda
Dravet Syndrome (DS), Lennox Gastaut Syndrome (LGS)
05/26
05/26
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1633
Europe, Japan, US, RoW
Lasmiditan, LY573144, Placebo
Eli Lilly and Company
Migraine
11/26
11/26
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1000
Europe, Japan, US, RoW
Lasmiditan, LY573144
Eli Lilly and Company
Migraine
01/28
01/28
NCT03734731: Cannabis Vs Opioids Pain Management Objective Testing Comparisons

Not yet recruiting
N/A
1000
NA
Monochromatic Infrared Photo Energy (MIRE), Transcutaneous Electrical Nerve Stimulation, Opioids, Cannabis, Marijuana
American Association of Sensory Electrodiagnostic Medicine
Chronic Pain, Circulatory Disorders
01/26
01/26
Reese, Randall
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

Recruiting
3
300
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Chronic Migraine
07/25
03/26
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

Recruiting
3
325
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Episodic Migraine
11/25
11/26
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1633
Europe, Japan, US, RoW
Lasmiditan, LY573144, Placebo
Eli Lilly and Company
Migraine
11/26
11/26
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1000
Europe, Japan, US, RoW
Lasmiditan, LY573144
Eli Lilly and Company
Migraine
01/28
01/28
NCT05412030: A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

Active, not recruiting
2
472
US
AFX3772, Prevnar 13, PCV13, Prevnar 20, PCV20
GlaxoSmithKline, Affinivax, Inc.
Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
07/26
07/26
McConnehey, Brock
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Remternetug, LY3372993, Placebo
Eli Lilly and Company
Alzheimer's Disease
04/29
10/30
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Active, not recruiting
3
1576
Japan, US, RoW
Orforglipron, LY3502970, Semaglutide
Eli Lilly and Company
Type 2 Diabetes
09/25
09/25
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

Recruiting
3
300
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Chronic Migraine
07/25
03/26
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

Recruiting
3
325
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Episodic Migraine
11/25
11/26
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting
3
2996
Japan, US
Donanemab, LY3002813, Placebo
Eli Lilly and Company
Alzheimer Disease
11/27
11/27
Kalidas, Kavita
CHALLENGE-MIG, NCT05127486: A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine

Checkmark Enrollment initiated in combination with Emgality for episodic migraine
Nov 2021 - Nov 2021: Enrollment initiated in combination with Emgality for episodic migraine
Completed
4
580
US
Galcanezumab, LY2951742, Rimegepant, Placebo
Eli Lilly and Company
Migraine, Episodic Migraine
05/23
05/23
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

Recruiting
3
300
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Chronic Migraine
07/25
03/26
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

Recruiting
3
325
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Episodic Migraine
11/25
11/26
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1633
Europe, Japan, US, RoW
Lasmiditan, LY573144, Placebo
Eli Lilly and Company
Migraine
11/26
11/26
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1000
Europe, Japan, US, RoW
Lasmiditan, LY573144
Eli Lilly and Company
Migraine
01/28
01/28
Taylor, Kelly
CHALLENGE-MIG, NCT05127486: A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine

Checkmark Enrollment initiated in combination with Emgality for episodic migraine
Nov 2021 - Nov 2021: Enrollment initiated in combination with Emgality for episodic migraine
Completed
4
580
US
Galcanezumab, LY2951742, Rimegepant, Placebo
Eli Lilly and Company
Migraine, Episodic Migraine
05/23
05/23
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

Recruiting
3
300
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Chronic Migraine
07/25
03/26
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

Recruiting
3
325
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Episodic Migraine
11/25
11/26
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1633
Europe, Japan, US, RoW
Lasmiditan, LY573144, Placebo
Eli Lilly and Company
Migraine
11/26
11/26
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1000
Europe, Japan, US, RoW
Lasmiditan, LY573144
Eli Lilly and Company
Migraine
01/28
01/28
GLY-200-03, NCT06259981: A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity

Active, not recruiting
2
75
US
GLY-200, Placebo
Glyscend, Inc.
Obesity
12/24
12/24
Moore, Joseph O
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

Recruiting
3
300
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Chronic Migraine
07/25
03/26
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

Recruiting
3
325
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Episodic Migraine
11/25
11/26
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1633
Europe, Japan, US, RoW
Lasmiditan, LY573144, Placebo
Eli Lilly and Company
Migraine
11/26
11/26
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1000
Europe, Japan, US, RoW
Lasmiditan, LY573144
Eli Lilly and Company
Migraine
01/28
01/28
NCT06143956: A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Recruiting
2
1040
US, RoW
LY3305677, LY3841136, Tirzepatide, Placebo, LY3549492
Eli Lilly and Company
Obesity, Overweight
06/26
09/26
NCT06230523: A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

Active, not recruiting
2
250
US, RoW
LY3841136, Placebo
Eli Lilly and Company
Obesity, Overweight and Obesity
06/25
09/25
NCT06603571: A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Recruiting
2
350
US, RoW
LY3841136, Tirzepatide, Placebo
Eli Lilly and Company
Obesity, Overweight
06/26
08/26
NCT06683508: A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

Active, not recruiting
2
275
US
LY3549492, Placebo
Eli Lilly and Company
Obesity, Overweight
04/26
09/26
Fernandez, Joel Garcia
PROACTIVE-HF, NCT04089059: IDE Trial Heart Failure NYHA Class III

Active, not recruiting
N/A
738
Europe, US
Cordella™ Pulmonary Artery Sensor System
Endotronix, Inc.
Heart Failure NYHA Class III
04/28
04/28
Phan, Han
RESPOND, NCT04488133 / 2020-003492-18: A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec

Active, not recruiting
4
46
Europe, US, RoW
Nusinersen, ISIS 396443, BIIB058, Spinraza
Biogen
Muscular Atrophy, Spinal
10/25
10/25
RECONNECT, NCT04977986 / 2021-002542-33: Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome

Active, not recruiting
3
215
Europe, US, RoW
ZYN002 - transdermal gel, cannabidiol formulated as a clear gel that can be applied to the skin (transdermal delivery), Placebo, Placebo Comparator, Matching Placebo
Zynerba Pharmaceuticals, Inc., Zynerba Pharmaceuticals, Inc.
Fragile X Syndrome
05/25
05/25
EBS-101-TD-391, NCT06021522: A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder

Recruiting
3
150
Europe, Canada, US, RoW
Ecopipam, Ecopipam Hydrochloride
Emalex Biosciences Inc.
Tourette Syndrome
12/26
03/27
MIS51ON, NCT03992430 / 2018-001762-42: A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD)

Active, not recruiting
3
160
Europe, US, RoW
Eteplirsen, AVI-4658, EXONDYS 51, EXONDYS
Sarepta Therapeutics, Inc., Sarepta Therapeutics, Inc.
Muscular Dystrophy, Duchenne
10/26
10/26
HOPE-3, NCT05126758: A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

Active, not recruiting
3
104
US
Deramiocel (CAP-1002), Cardiosphere-Derived Cells (CDCs), Placebo
Capricor Inc.
Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases, Neuromuscular Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn, Nervous System Diseases
12/25
12/27
D1AMOND, NCT05615220: Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults

Completed
3
216
Europe, Canada, US, RoW
Ecopipam Hydrochloride
Emalex Biosciences Inc.
Tourette Disorder
01/25
02/25
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

Recruiting
3
300
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Chronic Migraine
07/25
03/26
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

Recruiting
3
325
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Episodic Migraine
11/25
11/26
ASCEND, NCT05067790 / 2021-001294-23: A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam

Active, not recruiting
3
45
Europe, Japan, US, RoW
Nusinersen, BIIB058, Spinraza
Biogen
Spinal Muscular Atrophy
06/27
06/27
Fortify, NCT05775848: Study to Evaluate the Efficacy and Safety of BBP-418 (Ribitol) in Patients With Limb Girdle Muscular Dystrophy 2I (LGMD2I)

Active, not recruiting
3
81
Europe, US, RoW
BBP-418 (ribitol), Placebo
ML Bio Solutions, Inc.
Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)
07/27
07/27
NCT04336826 / 2020-000980-21: A Study to Evaluate the Safety and Pharmacokinetics of Ataluren in Participants From ≥6 Months to <2 Years of Age With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

Completed
2
6
US
Ataluren, PTC124
PTC Therapeutics
Nonsene Mutation Duchenne Muscular Dystrophy
08/23
08/23
MOMENTUM, NCT04004065 / 2019-000601-77: Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment

Checkmark From MOMENTUM trial for DMD
May 2021 - May 2021: From MOMENTUM trial for DMD
Checkmark Interim data from the MOMENTUM study
Dec 2020 - Dec 2020: Interim data from the MOMENTUM study
Checkmark Data from MOMENTUM trial for Duchenne muscular dystrophy
More
Terminated
2
62
Europe, Canada, US
Vesleteplirsen, SRP-5051
Sarepta Therapeutics, Inc.
Duchenne Muscular Dystrophy
10/23
02/25
PWS-001, NCT05879614: An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome

Withdrawn
2
20
US
NNZ-2591, Cyclo-L-Glycyl-L-2-Allylproline
Neuren Pharmaceuticals Limited
Prader-Willi Syndrome
06/25
06/25
NCT06332807: AAV Gene Therapy Clinical Study in Adult Classic PKU (PHEdom)

Recruiting
1/2
12
US
NGGT002
NGGT INC.
Phenylketonurias
12/30
12/30
DELIVER, NCT05524883 / 2021-005478-24: Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

Active, not recruiting
1/2
86
Europe, Canada, US, RoW
DYNE-251, Placebo
Dyne Therapeutics, Dyne Therapeutics, Inc
Duchenne Muscular Dystrophy (DMD)
11/29
11/29
NCT05683379: AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Boys With DMD

Recruiting
N/A
200
US
AAV8 DetectCDx
REGENXBIO Inc.
Duchenne Muscular Dystrophy
09/26
09/26
Moretz, Katherine McNaughton
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

Recruiting
3
325
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Episodic Migraine
11/25
11/26
NCT05067634 / 2020-005344-27: Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures

Recruiting
3
140
Europe, US, RoW
Xcopri
SK Life Science, Inc.
Partial Epilepsy
05/26
07/26
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1633
Europe, Japan, US, RoW
Lasmiditan, LY573144, Placebo
Eli Lilly and Company
Migraine
11/26
11/26
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1000
Europe, Japan, US, RoW
Lasmiditan, LY573144
Eli Lilly and Company
Migraine
01/28
01/28
Wilson, David R
NCT04154488: A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders

Completed
1/2
32
US
Mavorixafor, X4P-001
X4 Pharmaceuticals
Neutropenia
08/24
08/24
NCT01736592: Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration

Calendar Jan 2034 - Dec 2034: Data in Stargardt’s macular degeneration
Active, not recruiting
1/2
27
Europe, US
Long term follow up in all patients who received SAR422459 in previous study TDU13583
Sanofi
Stargardt's Disease
08/33
08/33
IMPRoVED-AF, NCT06935591: Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study

Not yet recruiting
N/A
384
Europe, US
Pulmonary Vein Isolation, vMap® + Pulmonary Vein Isolation
Vektor Medical, Veranex Switzerland SA
Atrial Fibrillation (AF)
10/27
12/27
NCT04165564: DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers

Active, not recruiting
N/A
85
US
Institutional standard of care, Biosamples of airway and blood
Boston University, Johnson & Johnson, American College of Radiology Imaging Network
Pulmonary Disease
12/26
12/26
NCT05412927: AngelMed Guardian® System PMA Post Approval Study

Recruiting
N/A
500
US
PMA P150009 AngelMed Guardian® System
Angel Medical Systems
Acute Coronary Syndrome
12/26
12/26
Boratto, Sandra
ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting
3
612
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Active, not recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
Soucie, Gary
QWINT-4, NCT05462756 / 2021-005878-25: A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections

Completed
3
730
Europe, US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Lispro (U100), Humalog, Insulin Glargine (U100), Basaglar
Eli Lilly and Company, Eli Lilly and Company
Type 2 Diabetes, Type 2 Diabetes Treated With Insulin
02/24
02/24
ATTAIN-OSA, NCT06649045: A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Recruiting
3
600
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
OSA, Overweight or Obesity
11/26
01/27
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

Recruiting
3
300
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Chronic Migraine
07/25
03/26
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Active, not recruiting
3
3000
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight, Overweight or Obesity
07/25
07/27
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

Recruiting
3
325
Europe, Japan, US, RoW
Galcanezumab, LY2951742, Placebo
Eli Lilly and Company
Episodic Migraine
11/25
11/26
TRIUMPH-3, NCT05882045: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Active, not recruiting
3
1800
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Cardiovascular Diseases
01/26
02/26
TRIUMPH-4, NCT05931367: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee

Active, not recruiting
3
405
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Overweight, Osteo Arthritis Knee
12/25
12/25
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
Diaz, Doris Perez
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1633
Europe, Japan, US, RoW
Lasmiditan, LY573144, Placebo
Eli Lilly and Company
Migraine
11/26
11/26
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1000
Europe, Japan, US, RoW
Lasmiditan, LY573144
Eli Lilly and Company
Migraine
01/28
01/28
Haller, Andrea
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1633
Europe, Japan, US, RoW
Lasmiditan, LY573144, Placebo
Eli Lilly and Company
Migraine
11/26
11/26
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1000
Europe, Japan, US, RoW
Lasmiditan, LY573144
Eli Lilly and Company
Migraine
01/28
01/28
Goldstein, Gary I
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1633
Europe, Japan, US, RoW
Lasmiditan, LY573144, Placebo
Eli Lilly and Company
Migraine
11/26
11/26
 

Download Options